Journey Medical (DERM) EPS (Weighted Average and Diluted) (2020 - 2026)
Journey Medical filings provide 6 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.04 for Q4 2025.
- On a quarterly basis, EPS (Weighted Average and Diluted) fell 150.0% to -$0.04 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.47, a 36.49% increase, with the full-year FY2025 number at -$0.47, up 34.72% from a year prior.
- EPS (Weighted Average and Diluted) hit -$0.04 in Q4 2025 for Journey Medical, up from -$0.09 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.8 in Q3 2023 to a low of -$1.89 in Q4 2021.
- Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.18 (2024), compared with a mean of -$0.38.
- Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 921.74% in 2021 and later surged 240.35% in 2023.
- Journey Medical's EPS (Weighted Average and Diluted) stood at -$1.89 in 2021, then skyrocketed by 68.25% to -$0.6 in 2022, then surged by 80.0% to -$0.12 in 2023, then surged by 166.67% to $0.08 in 2024, then crashed by 150.0% to -$0.04 in 2025.
- The last three reported values for EPS (Weighted Average and Diluted) were -$0.04 (Q4 2025), -$0.09 (Q3 2025), and -$0.16 (Q2 2025) per Business Quant data.